16 October 2020

leon and Evotec share nanosuspension downstream processing insights ahead of AAPS PharmSci 360

leon-nanodrugs GmbH, the leading enabler of nanotechnology for the pharmaceutical industry, will co-host a webinar exploring the downstream processing of nanosuspensions with strategic partner Evotec ahead of this year’s AAPS PharmSci 360 event.

The live webinar will be jointly presented by Pascale Clement, Chief Technology Officer at leon, and Paolo Gatti, SVP Pharmaceutical Development Scientific Direction at Evotec, and is scheduled to take place on October 20 at 12:30PM Eastern Daylight Time (EDT).

Under the title Nanosuspensions Downstream Processing – Strategies and Key Facts for Oral Dosage Forms, the webinar will provide background on the development of nanotechnologies in the early 1990s before focusing on the successful emergence of nanocrystals and other types of nanoparticles  as a vehicle for improving the oral bioavailability of poorly soluble drugs, and then exploring the production of oral medicines based on nano formulations.

The speakers will consider the benefits and disadvantages of commonly used techniques for converting nanosuspensions into solid materials, including their impact on the properties of nanosized particulates and in-vivo performance.

Pascale Clement, Chief Technology Officer at leon, said: “We are very excited to present this webinar alongside our partners at Evotec. Nanotechnology is on an accelerated growth curve right now as it presents pharmaceutical and biotechnology companies with an innovative answer to the challenge of poor solubility and bioavailability. In the case of orally administered drugs, the downstream processing stage is critical to ensure that nanosuspensions are converted in a way that maintains the integrity and efficacy of the formulation throughout the manufacturing process in a way that’s both cost-effective and scalable.”

To register for the event, please click here